

Aurore Perrot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7243957/publications.pdf>

Version: 2024-02-01

58
papers

3,779
citations

279487

23
h-index

168136

53
g-index

59
all docs

59
docs citations

59
times ranked

2927
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	0.6	43
2	Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma. <i>Leukemia</i> , 2022, 36, 881-884.	3.3	1
3	How I treat frontline transplantation-eligible multiple myeloma. <i>Blood</i> , 2022, 139, 2882-2888.	0.6	9
4	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 416-427.	5.1	54
5	Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. <i>Blood</i> , 2022, 139, 2666-2672.	0.6	12
6	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	3.3	81
7	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. <i>Blood</i> , 2022, 139, 2747-2757.	0.6	16
8	Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. <i>Journal of Infection</i> , 2022, 85, e104-e108.	1.7	29
9	Standardization of ¹⁸ F-FDG PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.	0.8	85
10	del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. <i>Blood</i> , 2021, 137, 1192-1195.	0.6	48
11	Multiple myeloma with hungry plasma cells. <i>British Journal of Haematology</i> , 2021, 193, 443-443.	1.2	0
12	Multiple Myeloma: Heterogeneous in Every Way. <i>Cancers</i> , 2021, 13, 1285.	1.7	15
13	Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. <i>Blood Advances</i> , 2021, 5, 2438-2446.	2.5	20
14	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	1.2	27
15	A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. <i>Blood Cancer Journal</i> , 2021, 11, 89.	2.8	49
16	Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. <i>Leukemia</i> , 2021, 35, 3600-3603.	3.3	11
17	Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. <i>Blood</i> , 2021, 138, 2686-2695.	0.6	11
18	Double-hit multiple myeloma with atypical t(11;14) cells. <i>British Journal of Haematology</i> , 2021, , .	1.2	0

#	ARTICLE	IF	CITATIONS
19	Risk and Response-Adapted Treatment in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3497.	1.7	10
20	Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database. <i>Vaccines</i> , 2020, 8, 722.	2.1	3
21	When dystrophic plasma cells do not recognize themselves in the mirror. <i>EJHaem</i> , 2020, 1, 408-408.	0.4	0
22	Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. <i>Haematologica</i> , 2020, 105, e480-483.	1.7	42
23	Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1323-1333.	0.6	18
24	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. <i>Blood</i> , 2020, 136, 39-39.	0.6	70
25	Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8538-8538.	0.8	4
26	Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?. <i>Hematological Oncology</i> , 2019, 37, 80-84.	0.8	15
27	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	6.3	435
28	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	13.9	684
29	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 29-38.	6.3	665
30	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1657-1665.	0.8	111
31	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN 503): final results of an openâ€label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019, 186, e35-e39.	1.2	12
32	Open Label Non-Randomized Phase II Study Exploring Â«Chemo-Free Â» Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase. <i>Blood</i> , 2019, 134, 346-346.	0.6	8
33	Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study. <i>Blood</i> , 2019, 134, 692-692.	0.6	42
34	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. <i>Blood</i> , 2019, 134, 1875-1875.	0.6	26
35	Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update. <i>Blood</i> , 2019, 134, 3152-3152.	0.6	4
36	Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8003-8003.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.. Journal of Clinical Oncology, 2019, 37, 8016-8016.	0.8	7
38	Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.. Journal of Clinical Oncology, 2019, 37, 8017-8017.	0.8	9
39	Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. Journal of Clinical Oncology, 2019, 37, 8035-8035.	0.8	4
40	Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. Cancer Medicine, 2018, 7, 539-548.	1.3	10
41	Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Bone Marrow Transplantation, 2018, 53, 749-755.	1.3	18
42	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, 2018, 131, 301-310.	0.6	216
43	Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 675-680.	1.8	23
44	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British Journal of Haematology, 2018, 183, 755-765.	1.2	41
45	Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). Blood, 2018, 132, 2778-2780.	0.6	18
46	Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Advances, 2018, 2, 2811-2813.	2.5	69
47	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood, 2018, 132, 2555-2563.	0.6	54
48	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 2018, 132, 2456-2464.	0.6	301
49	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of $\hat{\tau}$ SUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical Cancer Research, 2018, 24, 5219-5224.	3.2	24
50	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). Blood, 2018, 132, LBA-2-LBA-2.	0.6	30
51	Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. Journal of Clinical Oncology, 2017, 35, 2911-2918.	0.8	247
52	Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial. Blood, 2016, 128, 2138-2138.	0.6	6
53	Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO). Blood, 2016, 128, 2982-2982.	0.6	3
54	A PHASE 1/2 Clinical Trial of Brentuximab-Vedotin and Bendamustin in Elderly Patients with Previously Untreated Advanced Hodgkin Lymphoma (HALO STUDY. NCT identifier : 02467946): Preliminary Report. Blood, 2016, 128, 4154-4154.	0.6	5

#	ARTICLE	IF	CITATIONS
55	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. Blood, 2016, 128, 471-471.	0.6	12
56	Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du My��Lome (IFM). Blood, 2016, 128, 674-674.	0.6	16
57	Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies. Blood, 2016, 128, 927-927.	0.6	0
58	Revised international staging system allocation in the ICARIA��MM study: Practical challenges and impact on outcome. EJHaem, 0, , .	0.4	0